自闭症谱系障碍(autism spectrum disorders,ASD)是一种严重危害儿童身心的发育障碍。美国精神病协会发布《精神疾病诊断与统计手册》第5版(diagnostic and statistical manual of mental disorders-fifth edition,DSM-V)将ASD划归到神...自闭症谱系障碍(autism spectrum disorders,ASD)是一种严重危害儿童身心的发育障碍。美国精神病协会发布《精神疾病诊断与统计手册》第5版(diagnostic and statistical manual of mental disorders-fifth edition,DSM-V)将ASD划归到神经发育障碍类别下,其核心症状是持续的社会交流障碍以及重复刻板的行为。社会沟通与交往障碍对ASD个体的日常生活造成了严重负面影响,其主要表现之一:在知觉和理解他人面孔所传达的信息方面存在缺陷,进而导致在后续的社会交往中存在障碍,严重影响了ASD个体的正常生活。因而本文将从ASD个体面孔加工方面入手,重点从其知觉理解面孔加工的眼动特征、潜在神经机制和相应的干预策略来展开综述,对ASD个体面孔识别障碍的临床治疗有重要意义。展开更多
Objective:To determine the efficacy and safety of atomoxetinein adolescent subjects treated for attention-deficit/hyper activity disorder (ADHD) for up to 2 years. Study design:Data from13 atomoxetine studies (6 doubl...Objective:To determine the efficacy and safety of atomoxetinein adolescent subjects treated for attention-deficit/hyper activity disorder (ADHD) for up to 2 years. Study design:Data from13 atomoxetine studies (6 double-blind,7 open-label)were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders IV. Results:Of the 601 atomoxetine treated subjects in this meta-analysis,537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects havecompleted at least 2 years of treatment. The mean dose of atomoxetine at end point was 1.41 mg/kg/day. Mean ADHD Rating Scale IV,parent version,investigator-administered and-scored total scores showed significant improvement (P < 0.001)-over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period,99 (16.5%) subjects discontinued treatment due to lack of effectiveness,and 31 (5.2%) subjects discontinued treatmentdue to adverse events. No clinically significant abnormalities inheight,weight,blood pressure,pulse,mean laboratory values,or electrocardiography parameters were found. Conclusions:Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD,with no evidence of drug tolerance and no new or unexpected safety concerns.展开更多
文摘自闭症谱系障碍(autism spectrum disorders,ASD)是一种严重危害儿童身心的发育障碍。美国精神病协会发布《精神疾病诊断与统计手册》第5版(diagnostic and statistical manual of mental disorders-fifth edition,DSM-V)将ASD划归到神经发育障碍类别下,其核心症状是持续的社会交流障碍以及重复刻板的行为。社会沟通与交往障碍对ASD个体的日常生活造成了严重负面影响,其主要表现之一:在知觉和理解他人面孔所传达的信息方面存在缺陷,进而导致在后续的社会交往中存在障碍,严重影响了ASD个体的正常生活。因而本文将从ASD个体面孔加工方面入手,重点从其知觉理解面孔加工的眼动特征、潜在神经机制和相应的干预策略来展开综述,对ASD个体面孔识别障碍的临床治疗有重要意义。
文摘Objective:To determine the efficacy and safety of atomoxetinein adolescent subjects treated for attention-deficit/hyper activity disorder (ADHD) for up to 2 years. Study design:Data from13 atomoxetine studies (6 double-blind,7 open-label)were pooled for subjects age 12 to 18 with ADHD as defined by the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders IV. Results:Of the 601 atomoxetine treated subjects in this meta-analysis,537 (89.4%) completed 3 months of acute treatment. A total of 259 subjects (48.4%) are continuing atomoxetine treatment; 219 of these subjects havecompleted at least 2 years of treatment. The mean dose of atomoxetine at end point was 1.41 mg/kg/day. Mean ADHD Rating Scale IV,parent version,investigator-administered and-scored total scores showed significant improvement (P < 0.001)-over the first 3 months. Symptoms remained improved up to 24 months without dosage escalation. During the 2-year treatment period,99 (16.5%) subjects discontinued treatment due to lack of effectiveness,and 31 (5.2%) subjects discontinued treatmentdue to adverse events. No clinically significant abnormalities inheight,weight,blood pressure,pulse,mean laboratory values,or electrocardiography parameters were found. Conclusions:Two-year data from this ongoing study indicate that atomoxetine maintains efficacy among adolescents with ADHD,with no evidence of drug tolerance and no new or unexpected safety concerns.
